Oxford BioMedica
Discover Realise

Product licensing opportunities

Oxford BioMedica is seeking development and commercialisation partners for the following products. Click on each product for more information.

For more information on our licensing opportunities, please contact our Business Development team at licensing@oxfordbiomedica.co.uk.


OXB-201

OXB-201 is a gene-based treatment for neovascular “wet” AMD and could also be used for diabetic retinopathy (DR). OXB-201 aims to preserve and improve the vision of patients through anti-angiogenesis, the process of blocking the formation CESR 134(i), CESR 134(ii), (iv) of new blood vessels. The product uses the Company’s integrated LentiVector® delivery platform technology to deliver two genes encoding the anti-angiogenic proteins endostatin and angiostatin directly to the retina by injection.

The industry standard treatments for wet AMD and other related ocular conditions achieved global sales in excess of US$7.0 billion in 2013 (Source: Novartis, Roche, Regeneron). On the basis of pre-clinical data, it is anticipated that OXB-201 may require only a single administration. If confirmed, this would give the product a significant advantage over currently available treatments in the market that require frequent, repeated administration.

Click here to read more about our existing product portfolio

$7.0bn

Wet age-related macular degeneration (AMD), diabetic macular oedema, and retinal vein occlusion has a market size of $7.0 billion based on 2014 LUCENTIS®/Eylea sales (source: Novartis, Roche, Regeneron, Bayer)

OXB-301 (TroVax®)

OXB-301 (TroVax®) is a cancer vaccine that has completed 11 clinical trials in colorectal, renal and prostate cancer. It elicits a strong and readily definable immune response. Oxford BioMedica has identified a biomarker, using a simple blood test, which predicts both the magnitude of the induced 5T4 antibody response and treatment benefit. This enables us to identify those patients who are most likely to benefit from treatment with OXB-301 (TroVax®). Phase I / II investigator led studies underway. Recruitment to the SKOPOS (mesothelioma) study has now been completed and the data are being analysed.

 

Click here to read more about our existing product portfolio

$19.5bn

The cancer targeted therapies and immunotherapy market was $19.5 billion in 2009, forecast to increase to $36.8 billion in 2019

Facts

Innovation

Oxford BioMedica is committed to advancing the wider development of gene and cell therapy approaches by offering licences under its related IP